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 N, N-Dimethylacetamide (DMA) alters the ultrastructure of acrosome leading to infertility in rats.
 DMA impairs spermatogenesis by inhibiting the post-meiotic round and elongated spermatids within the testis.
 DMA distorts the mitochondrial and microtubular structure of sperm therefore, reducing the sperm motility.
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a b s t r a c t
N, N-Dimethylacetamide is an FDA approved solvent widely used in pharmaceutical industry to facilitate
the solubility of lipophilic, high molecular weight drugs with poor water solubility. However, the cyto-
toxic effects of DMA raises the concern about its use in clinical applications. In the present study, we
address the effect of DMA on spermatogenesis. Male Sprague Dawley rats were injected intra-
peritoneally for 8 weeks, once a week at a dose of 862 mg/kg. Analysis of reproductive parameters
revealed that DMA treated animals exhibit spermatid formation defects within the testis describing the
characteristics of oligozoospermia. A subsequent decrease in epididymal sperm concentration along with
distortion of sperm morphology was observed. The mitochondrial and microtubule organization in the
sperm is considerably modified by DMA. This disrupts the sperm kinetics thus decreasing the total and
progressive sperm motility. Finally, DMA treatment resulted in loss of fertility. Our results indicate that
exposure to DMA has a negative impact on spermatogenesis and leads to infertility in male rats by
inhibiting the post meiotic stages of sperm development. Therefore, the use of DMA in humans must be
closely monitored.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
N, N-Dimethylacetamide (DMA) is a widely used solvent due to
its relatively high boiling point, thermal stability and high purity
(Solomon et al., 1991). In industrial setting, it is applied for the
manufacturing of films and fibers (Malley et al., 1995). However,
exposure to DMA must be controlled due to its cytotoxic effects.
The primary organ following high-level exposure is the liver, where
the degree of damage is proportional to the exposure levels.
Exposure to massive doses can lead to damage to other organs as
well (Kennedy,1986). In addition to the chemical industry, DMA is a
widely used solvent in the pharmaceutical industry. It is the choice
of solvent in the manufacturing process of the antibiotic cefpo-
doxime proxetil, administered for the treatment of respiratory and
urinary tract infections (Rodriguez et al., 2003). DMA facilitates at a
high dose the preparation of intravenous formulations of busulfan,
a chemotherapeutic agent administered prior to hematopoietic
stem cell transplantation or bone marrow transplantation in both
adults and children (Hassan, 1999; Trame et al., 2013). Ideally, as a
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pharmaceutical excipient, DMA should be devoid of any biological
activity. However, in 2017, we showed that DMA binds bromodo-
mains and may be useful for the treatment of osteoporosis (Ghayor
et al., 2017). Subsequently, we have shown that it can act as a
therapy for TNF-a compromised bone healing (Chen et al., 2019).
Further research has also focused on its role in female reproduction
where it regulates pro-inflammatory response associated with
endotoxin to prevent preterm birth (Gorasiya et al., 2018). Together,
these results show that DMA, being an organic solvent is biologi-
cally active. It acts via binding to bromodomain proteins. Bromo-
domain containing proteins are trans-acting readers that recognize
acetylated lysine. They act as scaffolds to recruit macromolecular
complexes that alter the chromatin accessibility to transcriptional
machinery (Prinjha et al., 2012). The BET (bromodomain and extra
terminal) family of bromodomain containing proteins consist of an
N-terminal bromodomain and a C-terminal ET (extra-terminal)
domain that is unique to this group of proteins. The four
mammalian BET proteins include BRD2, BRD3, BRD4 and the testis
specific BET protein, BRDT (Florence and Faller, 2001). They are
involved in various cellular processes including proliferation and
differentiation. During spermatogenesis, each of the BET genes is
expressed at specific time and are essential for proper spermato-
genesis process (Taniguchi, 2016).
Spermatogenesis is a complex and tightly regulated process by
which spermatozoa are produced from spermatogonial stem cells.
This process involves mitosis of spermatogonia and meiosis of
spermatocytes, leading to the production of spermatids. During
spermiogenesis, the spermatids undergo significant morphological
transformations, leading to the production of fully differentiated
mature spermatozoa (Holstein et al., 2003). The progression
through each of the stages is a co-ordinated action of multiple
genes and proteins including the proteins from the BET family
(Berkovits and Wolgemuth, 2013). BRD2 associates with tran-
scription factor E2F to induce transcriptional activation of genes,
especially during the late spermatocyte stages of spermatogenesis
(Sinha et al., 2005). BRD4 plays an important role during sper-
miogenesis by forming a ring like structure around the spermatid
nuclei (Bryant et al., 2015). Binding interference studies have
shown that DMA reduced the binding capacity of BRD2 and BRD4 to
the acetyl lysine sites (Ghayor et al., 2017). Previously, it has been
shown that exposure to DMA results in a decrease in relative testis
weight along with degeneration of seminiferous tubules (R.
Valentine et al., 1997). However, the mechanism by which DMA
affects spermatogenesis is still elusive.
In the present study, we show that intraperitoneal injections of
DMA in rats cause morphological and transcriptional alterations in
sperm by inhibiting the post meiotic stages of spermatogenesis.
This raises a concern about DMA as an excipient in pharmaceutical
formulations and its effect on the patient’s reproductive health.
2. Methods
Animal experiments: All animal procedures met the ARRIVE
guidelines approved by the Animal Ethics Committee of the local
authorities (Veterin€aramt, Canton Zurich, project codes: 40/2012
(approved on the 2 April 2012) and 068/2015 (approved on the 31
July 2015), and follow the EU Directive 2010/63/EU for animal. Male
Sprague-Dawley rats (6 weeks old) were purchased from Charles
River Laboratories. After acclimatizing the animals to the animal
facility environment for two weeks, they were randomly divided
into two groups: DMA treatment group and a control group (PBS).
In three independent experiments, 16 animals (8 per group) were
used for body, testis and epididymal weight and Computer Assisted
Sperm Analysis. For subsequent experiments including histological
analysis, TUNEL assay, qPCR analysis, ANV determination (germ cell
counting), 5 animals from the initial eight animals per group were
randomly chosen. Volume of DMA to be injected was one third of
the LD50 (862 mg/kg). This dose was chosen from our previous
studies of DMA on rats (Ghayor et al., 2017). In addition, a pilot
study with n ¼ 3 showed a significant decrease in sperm count and
alteration of seminiferous epithelium (data not shown), therefore
the chosen dose was continued. One third of the lethal dose was
calculated as previously described (Bartsch et al., 1976). Animals
were injected once per week, intra-peritoneally for eight consec-
utive weeks, which is equivalent to one spermatogenesis cycle in
rats. The injection volume of each dose was 800 ml and animals
were weighed weekly to calculate the actual volume of chemicals.
The control animals received the same volume of PBS. Animals
were checked three times a week for any physiological side effects.
After eight weeks, the animals were sacrificed by CO2 asphyxiation
and the blood was collected by aortal puncture. The clotted blood
was centrifuged at 2000 rpm for 20 min to collect the serum. The
serum was stored at 80 for hormonal analysis. Liver, testis and
epididymis were collected in appropriate medium for further
analysis.
For mating experiments, one male was mated with one female
and the number of pups born were recorded.
Hormonal analysis: Serum Follicular Stimulating Hormone
(FSH), Luteinizing Hormone (LH) and Testosterone were measured
using the immunoassay kits from Cloud Clone Corp. (Product No.
CEA830Ra, CEA441Ra, CEA458Ge) according to manufacturer’s
protocol.
Computer Assisted SpermAnalysis (CASA): The left epididymis
was collected in HTF medium (Irvine Scientific, Article number
90126). For sperm counting, caudal epididymis was carefully cut,
punctured using a syringe needle and incubated in prewarmedHTF
medium for 10min at 37 C. The spermwere allowed to swim out in
1mL of HTF medium and then collected in a 1.5 mL Eppendorf tube.
The 1 mL sperm sample was carefully mixed and was further
diluted 1:100 (1 mL sperm sample and 99 mL HTF medium). 30 mL of
the diluted samplewas placed on a slide (Leja slides formotility and
concentration analysis, Microptic) and observed under the micro-
scope attached to Computer Assisted Sperm Analyser (Hamilton)
that provided measure of the sperm count, motility, progressive
motility and other parameters. All sperm parameters were
measured in 10 different fields on the slide.
12 different CASA parameters were recorded. One measure of
sperm number (sperm count) and two measures of sperm motility
(percentage motility and progressive motility) were recorded.
Percentage motility records the percentage of total progressive and
non-progressively motile sperms. Progressive motility records the
number of sperms that move in a straight line or large circles.
Straight line velocity (VSL) records the time-average velocity of a
sperm head along the straight line between its first and last
detected positions. Curvilinear velocity (VCL) records the average
velocity measured over the actual point-to-point track followed by
the cell. The time-average velocity (VAP) records the sperm head
along its spatial average trajectory (i.e. smoothed version of VCL).
Amplitude of lateral head displacement (ALH) is the maximum
lateral displacement of a sperm head about its spatial average
trajectory (i.e. track width). Linearity (LIN) is the linearity of the
curvilinear trajectory calculated as VSL/VCL  100. Straightness
(STR) is the LIN of the sperm average path calculated as VSL/
VAP  100. Beat cross frequency (BCF) is the time-average rate at
which the curvilinear sperm track crosses its average path trajec-
tory. The elongation ratio of minor to major axis of each sperm
nucleus and area of sperm head in micrometre square were also
recorded (Sloter et al., 2006).
Morphological analysis of sperm: For morphological analysis,
N. Khera et al. / Chemosphere 256 (2020) 1270012
sperm were isolated from caudal epididymis as explained before.
10 mL of 1:100 diluted sperm suspension was smeared on a glass
slide. The slides were dipped in bouin’s solution (Sigma-Aldrich)
overnight and then stained with 2% eosin solution (Sigma-Aldrich)
for 5 min. The slides were observed under the microscope (Leica
Microsystems, Wetzlar, Germany) for abnormalities. 200 sperms
were analysed per sample in a blinded manner for abnormal shape
of the head (broken head, pinhole head and flattened head), bent
neck and tail abnormalities (headless tail, short tail) as previously
described (Demirci and Sahin, 2019). Percentage of normal and
abnormal sperms was recorded ((number of normal sperms or
sperms having the abnormality/200) *100).
Transmission ElectronMicroscopy: Sperm isolated from cauda
epididymis were fixed with 2.5% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.35) for 1 h and rinsed three times with
0.1 M sodium cacodylate buffer for 5 min each. After centrifugation,
the specimens were sequentially treated with 1% OsO4 in 0.1 M
sodium cacodylate buffer for 1 h at 0 C and with 2% uranyl acetate
in H2O for 1 h at 4
C, with three H2O rinsing steps (5 min each)
between each step. The final pellet was immobilized with 2% of
Difco Noble Agar (BD Biosciences, Allschwil, Switzerland) in H2O,
dehydrated in an ethanol series and embedded in Epon/Araldite
(Sigma-Aldrich, Buchs, Switzerland). Ultrathin (70 nm) sections
were contrasted with Reynolds lead citrate and examined with a
CM100 transmission electronmicroscope (Thermo Fisher Scientific,
Eindhoven, The Netherlands) at an acceleration voltage of 80 kV
using an Orius 1000 digital camera (Gatan, Munich, Germany).
Scanning Electron Microscopy: Sperm suspensions were fixed
with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH
7.35) and subsequently centrifuged onto 12 mm cover glasses using
a Cytospin 2 centrifuge (Thermo Fisher Scientific, Schwerte, Ger-
many) at 40 g for 6 min. Cover glasses with attached sperm were
rinsed three times with PBS (pH 7.35) and post-fixed with 1% OsO4
in PBS for 30 min and rinsed 2 times with PBS prior to dehydration
in a sequence of increasing ethanol concentrations (70%, 100%).
Samples were incubated in 100% hexamethylsilazane for 1 h and
finally air dried overnight. Samples were mounted on aluminium
stubs using conductive carbon tabs, coated with 4 nm of platinum
in a CCU 010 sputtering device (Safematic, Bad Ragaz, Switzerland)
and imaged in a Supra 50 VP scanning electron microscope at an
acceleration voltage of 4 kV using the Everhart Thornley secondary
electron detector (Zeiss, Oberkochen, Germany).
Haematoxylin and eosin staining: Testis and epididymis were
collected in Bouin’s solution. Liver was collected in formalin. The
samples were sent to Sophistolab, Muttenz, Switzerland for prep-
aration of histological sections and Haematoxylin and Eosin (H&E)
stained slides. Briefly, the tissues were fixed in Bouin’s solution,
embedded in paraffin, sectioned using a microtome at 5 mm
thickness. The sections were stained with Hematoxyllin and Eosin
and were analysed blindly by 2 different experimenters.
Measurement of seminiferous tubule diameter: Twenty
seminiferous tubules were randomly selected from each H&E
stained testicular section, and the diameter was measured using
the Cell Sense Entry™ software of CKX53 Olympus (Tokyo, Japan)
microscope. The diameter was measured as the shortest distance
between two parallel tangent lines of the outer edge of one tubule.
The measurements were done blindly by the experimenter.
TUNEL Assay: Tunnel assay was performed to detect the
apoptotic cells within the seminiferous tubules using the Dead-
End™ Colorimetric TUNEL System (Promega USA) according to the
manufacturer’s protocol. TUNEL positive cells were counted in 20
random seminiferous tubules.
qPCR analysis: RNA was extracted using TRIzol reagent (Invi-
trogen). RNA quantity and quality (A260/A280 and A260/A230) was
determined using Nanodrop 2000 Spectrophotometer
(ThermoFisher). 1 mg of RNA per sample was reverse transcribed
into cDNA using iScript reverse transcription supermix (Bio-Rad).
RT-qPCR was performed using gene-specific primers (Supplemen-
tary Table) with SsoAdvanced universal SYBR green supermix and
the CFX Connect real-time system (Bio-Rad). Gene expression was
normalized to the reference gene beta actin using the comparative
CT method.
Mitochondrial Membrane Potential (MMP) measurement
and Flow cytometry: Sperm suspension from caudal epididymis
(10 million sperm/mL) was incubated with 100 nM of Mito-
Tracker™ Deep Red FM (Invitrogen™) for 20 min at 37 C in dark as
previously described (Hallap et al., 2005). MitoTracker™ Deep Red
FM was excited by 640 nm laser of BD FACS Canto II and the
emission was recorded in 660/20 channel. Ten thousand events
were recorded per sample. The decrease inMitoTracker™ Deep Red
FM fluorescence in DMA compared to PBS was calculated for
comparative analysis.
Cell counting for testis: For histological analyses, Bouin’s fixed,
paraffin embedded tissue sections were stained with H&E. Testic-
ular cell composition was estimated using standard stereological
techniques involving point counting of cell nuclei to determine the
nuclear volume per testis of Sertoli cells and different maturational
stages of germ cells, as previously described (Welsh et al., 2009). In
brief, cross sections of testis from PBS control and DMA treated
groups were examined using 63x objective fitted to Zeiss AxioScope
A1 and a 121-point eyepiece graticule (Leica Microsystems, Wet-
zlar, Germany). Applying a systematic sampling pattern from a
random starting point, 32 microscopic fields (3872 points) were
counted for each animal. Points falling over Sertoli cell or germ cell
nuclei, seminiferous epithelium, interstitium, seminiferous tubule
lumenwere scored, and they were expressed as relative (%) volume
per testis. For Sertoli cells and germ cell types including sper-
matogonia (Sg), spermatocytes (Sc), round (rSd) and elongated
(elSd) spermatids, the values for percent nuclear volume were
converted to absolute nuclear volumes per testis by reference to
testis volume (¼weight) because shrinkage was minimal.
3. Results
DMA decreases testis weight and tubular diameter: After
eight weeks of DMA treatment, the testis of DMA treated animals
appeared slightly smaller than PBS controls (Fig. 1A). Although
there was no change in the body weight, a significant decrease in
testis weight was observed in DMA treated animals (1.80 ± 0.10 vs
1.61 ± 0.13) (Fig. 1B and C). Measurement of seminiferous tubule
diameter and analysis of H&E sections of testis showed that the
seminiferous tubular diameter was significantly lower in DMA
treated animals compared to PBS. Magnified view of the seminif-
erous tubules revealed degeneration of germ cells especially in the
inner layers of the tubule (Fig. 1D and E).
DMA affects spermatid formation within testis: To determine
the germ cells that DMA targets, we used the standard stereological
techniques to determine the ANV (Absolute Nuclear Volume) per
testis for Spermatogonia (Sg), Spermatocytes (Sc), round sperma-
tids (rSd), elongated spermatids (elSd), total spermatids (tSd) and
Sertoli cells (SC). We found that while there was no significant
change in ANV of Sg, Sc, rSd and SC; elSd in testis from DMA treated
animals show a decrease of 31.14%. As a result, tSd (rSd and elSd)
also decrease by 21.6% in DMA treated animals (Table 1).
Measurement of Apoptosis: To determine whether the
decrease in testis weight, diameter of seminiferous tubules and
degeneration of elongated spermatids in the testis can be linked to
apoptosis, we performed TUNEL assay. A significant increase in
number of tubules with apoptotic cells and number of TUNEL-
positive cells per tubule after DMA treatment was observed
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(0.6 ± 0.55 vs 7.39 ± 1.00) (Fig. 1F).
Gene expression analysis: To study the changes at the level of
gene expression, we performed qPCR for germ cell markers that
play key roles at different stages of spermatogenesis: plzf for
spermatogonia (Costoya et al., 2004), aurkc and plk1 for sper-
matocytes (Quartuccio and Schindler, 2015; Jordan et al., 2012),
tnp1, tnp2, prm1, prm2, pcsk4 and odf1 for spermatids (Bao and
Bedford, 2016; Gyamera-Acheampong and Mbikay, 2009; Yang
Fig. 1. Changes in testis weight, body weight, apoptosis and gene expression in PBS and DMA treated animals. (A) Representative image of gross anatomy of testis from PBS and
DMA treated animals. (B) Effect of DMA treatment on testis weight (n ¼ 8), (C) body weight (n ¼ 8) and (D) Diameter of seminiferous tubules (n ¼ 5). (E) H&E staining of testicular
sections. Square indicates the enlarged image area. Black arrows indicate lumen of seminiferous tubules (scale bar: 200 mm) (n ¼ 5). (F) Number of TUNEL positive cells per tubule as
indicated by black arrows in PBS and DMA treated animals (Scale bar: 100 mm) (n ¼ 5). (G) Quantitative RT-PCR analysis of genes expressed at different stages of sperm maturation
and sertoli cells (n ¼ 5). Data represents mean ± s.d. (*p < 0.05, **p < 0.01, obtained by two tailed student t-test). (For interpretation of the references to color in this figure legend,
the reader is referred to the Web version of this article.)
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et al., 2012), and sox9 and tubb3 for sertoli cells (Hemendinger
et al., 2002; De Gendt et al., 2011). Although there was no change
in gene expression of spermatogonia, spermatocytes and sertoli
cells markers, a significant decrease in the expression of spermatids
markers was observed in DMA treated animals (Fig. 1G).
DMA impairs sperm count and motility: Once elongated, the
sperm producedwithin the testis, migrate to the epididymis to fully
mature and gain motility (Bedford, 2015). To evaluate the effect of
DMA on mature sperm leaving the testis, we analysed the epidid-
ymal parameters. After 8 weeks of injections, the weight of the
epididymis was significantly reduced in DMA treated animals
compared to PBS (1.01 ± 0.19 vs 0.74 ± 0.15) (Fig. 2A). Next, we
performed CASA and observed a 73.6% decrease in sperm concen-
tration in DMA treated animals compared to PBS (27.09 ± 20.33
million/mL vs 102.66 ± 32.46 million/mL) along with a 64.9%
decrease in motility (Fig. 2B and C and supplementary videos 1
(PBS) and 2 (DMA)). The decrease in sperm count was consistent
with the reduction in number of total and elongated spermatids
within the testis. There was also a significant decrease in progres-
sive motility (Fig. 2D). Moreover, we observed a significant reduc-
tion in the track speed (VCL) and area of sperm head (Table 2).
Histological analysis of H&E stained epididymis sections confirmed
the presence of a lower sperm count after DMA treatment (Fig. 2E).
Supplementary video related to this article can be found at
https://doi.org/10.1016/j.chemosphere.2020.127001
DMA decreases Mitochondrial Membrane Potential (MMP):
High sperm motility has been reported to be significantly associ-
ated with high mitochondrial functionality (Zhang et al., 2016). To
test if the reduction in sperm motility observed in DMA treated
group can be related to changes in mitochondrial membrane po-
tential, we stained the sperm isolated from caudal epididymis with
mitotracker deep red. Out of the total sperm, 29.22% of the DMA
treated sperm showed lower mitotracker staining and therefore
lower MMP compared to the PBS group (99.45 ± 0.15 vs
70.36 ± 5.10) (Fig. 3). This finding is consistence with the decrease
in sperm motility after DMA treatment observed by CASA.
DMA causes abnormal morphogenesis of sperm: In addition
to the quantitative loss of sperm, we observed morphological ab-
normalities in the sperm isolated from the cauda epididymis of
DMA treated animals (Fig. 4A). This included abnormal shape of the
Table 1
Composition of different cell types in the testis from PBS and DMA treated animals.
Germ cell type PBS DMA
Total Germ cells ANV (mg) 255.08 ± 25.34 237.154 ± 17.45
Spermatogonia ANV (mg) 9.51 ± 3.30 9.35 ± 2.86
Spermatocytes ANV (mg) 109.23 ± 14.90 113.47 ± 17.67
Total Spermatids ANV (mg) 139.56 ± 25.94 109.47 ± 27.38*
Round Spermatids ANV (mg) 98.45 ± 25.99 74.36 ± 19.40
Elongated Spermatids ANV (mg) 47.19 ± 3.75 32.39 ± 8.20**
Sertoli cell ANV (mg) 29.45 ± 6.39 29.05 ± 7.33
Data represent mean ± s.d. (*p < 0.05; **p < 0.01, obtained by two tailed student t-
test), n ¼ 5. ANV: Absolute Nuclear Volume.
Fig. 2. Effect of DMA on sperm count and motility (A) Changes in epididymis weight (n ¼ 8), sperm count, (C) sperm motility and (D) progressive motility in PBS and DMA treated
animals (n ¼ 8). (E) H&E staining of epididymis sections (scale bar: 100 mm) (n ¼ 5). Data represents mean ± s.d. (**p < 0.01, obtained by two tailed student t-test). (For inter-
pretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Table 2
Measurement of CASA parameters in epididymal sperm of PBS and DMA treated
animals.
Parameter PBS DMA
Path Velocity VAP mm/s 195.5875 ± 16.86 164.275 ± 44.18
Prog. Velocity VSL mm/s 125.625 ± 8.20 113.875 ± 54.00
Track Speed VCL mm/s 387.025 ± 37.63 301.0625 ± 59.87**
Lateral Amplitude ALH mm 18.7625 ± 1.59 15.8625 ± 5.09
Beat Frequency BCF Hz 29.0125 ± 1.40 28.3125 ± 4.64
Straightness STR % 61.75 ± 2.76 66.25 ± 7.53
Linearity LIN % 33.375 ± 2.13 39.25 ± 9.97
Elongation % 28.625 ± 3.78 25.625 ± 6.94
Area mm sq 308.975 ± 67.97 162.375 ± 52.65**
Data representmean± s.d. (**p< 0.01, obtained by two tailed student t-test) (n¼ 8).
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head (broken head, pinhole head and flattened head), bent neck
and tail abnormalities (headless tail, short tail). Quantification re-
sults indicated that nearly 56% of the total sperm had at least one
abnormality after DMA treatment (Fig. 4B). Scanning electron mi-
crographs showed multiple malformations of the DMA treated
head as well (Fig. 4C).
To determine the appearance of chromatin, the organization of
microtubules and the acrosome structure, we performed ultra-
structural analysis of sperm isolated from cauda epididymis by
transmission electron microscopy. We observed appearance of
multiple holes within the nucleus of sperm in DMA treated group.
Compared to PBS group, DMA treatment compromised the
Fig. 3. DMA treatment affects mitochondrial membrane potential (MMP): (A) Representative images of Mitotracker deep red dot plots for PBS and DMA treated animals. (B)
Number of Mitotracker positive sperm in DMA compared to PBS controls (n ¼ 3). Data represents percentage of PBS. (**p < 0.01 obtained by two tailed student t-test). (For
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Abnormal morphogenesis of sperm in DMA treated animals. (A) Morphology of (a) normal PBS and (bed) abnormal DMA treated sperm under light microscope. Sperm
were stained with eosin. Black arrows represent distorted head (b), neck (c) and (d) tail structures after DMA treatment (Scale bar: 50 mm). (B) Percentage of normal and abnormal
sperm in PBS and DMA treated animals (n ¼ 3). (C) SEM images of sperm heads from (a) PBS controls and (bef) DMA treated animals (scale bar a,d,e,f: 1 mm; b,c: 2 mm). Data
represents mean ± s.d. (**p < 0.01, obtained by two tailed student t-test). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version
of this article.)
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structure of middle piece and acrosome (Fig. 5). Epididymal sperm
from PBS animals had normal ‘’9 þ 2’’ motile cilia axonemal
structure. Other accessory structures were also well organised.
However, in DMA treated animals, sperm had multiple axonemal
anomalies like incomplete ‘’9 þ 2’’ core axonemal structure, mis-
positioned outer dense fibers (ODF) and improper spatial organi-
zation of the middle piece and mitochondrial structure (Fig. 5). All
these anomalies are associated with motility problems.
DMA causes infertility in rats: The head and acrosome struc-
ture are required for fertilization of the egg (Bhakta et al., 2019).
Since these structures were compromised after DMA treatment, the
effect of DMAwas observed on fertility of these rats. Male rats were
injected intraperitoneal with either PBS or DMA. After eight weeks,
the injections were stopped, and each male was mated with one
female. Both PBS and DMA produced equal number of litters.
However, DMA treated animals produced a significantly lower
number of pups (Fig. 6A). In the next set of experiments, additional
injections for three more weeks after the initial 8 weeks resulted in
complete infertility in DMA treated animals as no pups were born
(Fig. 6B) despite proper mating as was evident by presence of
Fig. 5. Ultrastructural analysis of sperm using Transmission electron microscopy (TEM): PBS animals have (a) normal acrosomal layer around the nucleus, (b) properly
organised middle piece, (c) outer dense fibers, mitochondria (black arrows) and (d) 9 þ 2 microtubule structures. Sperm from DMA treated animals show (e) abnormal nucleus with
multiple holes and degenerated acrosomal layer, (f) distorted middle piece, (g) dis-organised mitochondria and outer dense fibers, (Black arrows) and (h) abnormal 9 þ 2
microtubule structure (n ¼ 3). Scale bar: a: 1 mm; b,c and d: 5 mm; c and g: 1 mm; d and h: 300 nm.
Fig. 6. Effect of DMA on fertility: Number of pups born per animal in PBS and DMA
treated animals after (A) 8 weeks (n ¼ 6) and (B) 11 weeks (n ¼ 3) of treatment. Data
represents mean ± s.d. (**p < 0.01, obtained by two tailed student t-test).
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sperms on vaginal smears before the 21 days gestation period.
(Supplementary Fig. 1).
DMA does not alter the levels of sexual hormones: To deter-
mine if the loss of fertility after DMA treatment can be attributed to
changes in sexual hormonal levels, we performed ELISA for Follic-
ular stimulating hormone, Luteinizing Hormone and testosterone
in serum.We found no significant change in serum levels of FSH, LH
or testosterone (Fig. 7).
4. Discussion
In the current study, we have shown that intra-peritoneal in-
jections of DMA affect spermatogenesis and cause infertility. Our
results also indicate which phase of male germ cell development is
disturbed by DMA treatment. Germ cell counting and histological
analysis showed a decrease in number of total and elongated
spermatids, and degeneration of inner layers of seminiferous tu-
bules respectively. However, the outer layers were preserved
without changing the number of spermatogonia or spermatocytes.
Concomitantly, the gene expression analysis showed no change in
expression of spermatogonia and spermatocyte markers but a
significant decrease in post meiotically expressed genes in DMA
treated animals. All these results concluded that DMA acts in a post
meiotic manner to inhibit spermatogenesis.
A decrease in epididymal sperm concentration, deriving from a
decrease in total and elongated spermatid counts within the testis
displayed characteristic oligozoospermia (Guerri et al., 2019) in rats
injected with DMA. Oligozoospermia is often followed by poor
sperm motility and abnormal morphology reflecting qualitative
and quantitative defects in spermatogenesis (McLachlan, 2013).
Similar results were observed in sperm after DMA treatment.
Previous studies have shown that either genetic knockdown of
testis specific BET protein, BRDT or its inhibition by small molecule
JQ1 affects spermatogenesis. BRDT is expressed during pachytene
spermatocyte, diplotene spermatocyte, and round spermatid stages
(Shang et al., 2007; Matzuk et al., 2012). To examine the effect of
DMA on BRDT we performed Alpha screen assay and observed that
DMA inhibits BRDT with a half-maximal concentration (IC50) of
approximately 21 mM (Supplementary Fig. 2). Such a high IC50
value indicates that the effects caused by DMA are not specific to
BRDT inhibition, since the peak-concentration of DMA in rats just
after injection is 9.8 mM. This result was consistent with the germ
cell counting where we observed that DMA has no effect on the
number of spermatocytes or round spermatids within the semi-
niferous tubules, where BRDT is expressed.
While BRDT is expressed maximally in spermatocytes, the
expression of BRD4 is increased during spermiogenesis. BRD4
forms a ring like structure around the acrosome. Acrosomal mutant
mice lack this ring structure and show characteristic features of
human globozoospermia leading to improper sperm elongation
and infertility (Bryant et al., 2015). In a previous study, our lab has
shown that DMA inhibits BRD4 with a half-maximal concentration
(IC50) of 6mM (Ghayor et al., 2017). This explains the effects of DMA
treatment on spermatogenesis including compromised acrosomal
structure, decreased number of total and elongated spermatids,
and loss of partial or complete fertility.
It was of interest to note that DMA treated animals share fea-
tures with previously studied animal models that were deficient
with genes expressed during post meiotic stages. A significant
decrease in spermmotility and reduced fertility is observed in DMA
treated animals as well as in tnp1 deficient mousemodels (Yu et al.,
2000). Multiple sperm head abnormalities and malformed acro-
somal layer around the nucleus was common feature of both DMA
treated animals and tnp2 null mice (Adham et al., 2001). Loss of
ODF1, one of the main proteins of sperm tail results in formation of
multiple headless tails. Morphological analysis of sperm from DMA
treated animals showed similar tail abnormalities. In addition, mis-
organised mitochondrial sheath was also a shared characteristic for
both odf1 deficient mice and DMA treated animals (Yang et al.,
2012). We observed a significant decrease in gene expression of
tnp1, tnp2 and odf1 in testis of DMA treated animals. This explains
the similarities of compromised reproductive parameters in DMA
treated and tnp1, tnp2 and odf1 deficient animals.
Previous studies have discussed about the hepatotoxic effects of
DMA in rodents (Horn, 1961; Hundley et al., 1994; Solomon et al.,
1991). Data on toxic effects of DMA in humans is scarce. In
humans, DMA is injected as a solubilizer, along with busulfan
treatment in children during chemotherapy. The total concentra-
tion of DMA administered per regimen in a patient can be up to 105
mmoL (Trame et al., 2013; Oechtering et al., 2006). Hempel et al.
reported that DMA is not toxic even at high doses since it is rapidly
cleared from the body. However, the effect of DMA on spermato-
genesis was not monitored in that study (Hempel et al., 2007). By
injecting DMA in rats, at a much lower dose than that used in
humans, we have shown that this small chemical inhibits
spermatogenesis.
5. Conclusion
In conclusion, the present study demonstrates that DMA, an FDA
approved drug excipient, previously characterized as a bromodo-
main inhibitor, inhibits the spermatogenesis process leading to
infertility in male rats. The observed oligozoospermia induced by
DMA results from a decrease in number of total and elongated
spermatids within the testis, thus acting only post-meiotically,
leading to a decrease in sperm count in the epididymis. Further-
more, the sperm motility and mitochondrial membrane potential
are also compromised. The consequence of the observed distortion
in acrosomal structure is a partial or complete infertility of DMA
treated animals. Since DMA is applied clinically at high dosages, the
effect of DMA on spermatogenesis in humans during clinical ap-
plications should be closely monitored.
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